Chris Viehbacher, Biogen CEO (Suzanne Kreiter/The Boston Globe via Getty Images)
July 25, 2023 11:35 AM EDTUpdated July 28, 08:29 AM
Pharma

Three take­aways and three burn­ing ques­tions for Chris Viehbacher's cost-cut­ting fu­ture at Bio­gen

Andrew Dunn

Senior Biopharma Correspondent

Chris Viehbach­er has un­veiled his most dra­mat­ic move yet as Bio­gen’s CEO, aim­ing to save $1 bil­lion per year with a cost-cut­ting plan to chart …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times